206. Fragile X syndrome
98 clinical trials, 73 drugs (DrugBank: 27 drugs), 46 drug target genes, 57 drug target pathways
Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-004349-42-ES (EUCTR) | 16/08/2012 | 21/05/2012 | A study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome | A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome. | Fragile X Syndrome (FXS) MedDRA version: 14.1;Level: LLT;Classification code 10025463;Term: Major depressive disorder, single episode;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] | Product Name: mGlu5 antagonist Product Code: Ro 491-7523/F18 Other descriptive name: mGlu5 antagonist Product Name: mGlu5 antagonist Product Code: Ro 491-7523/F19 Other descriptive name: mGlu5 antagonist | F. Hoffmann-La Roche Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 180 | France;United States;Mexico;Canada;Argentina;Spain;Peru;Chile;United Kingdom;Sweden | |||
| 2 | EUCTR2011-004349-42-GB (EUCTR) | 16/07/2012 | 25/04/2012 | A study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome | A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome. | Fragile X Syndrome (FXS) MedDRA version: 14.1;Level: LLT;Classification code 10025463;Term: Major depressive disorder, single episode;System Organ Class: 100000004873;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] | Product Name: mGlu5 antagonist Product Code: Ro 491-7523/F18 Other descriptive name: mGlu5 antagonist Product Name: mGlu5 antagonist Product Code: Ro 491-7523/F19 Other descriptive name: mGlu5 antagonist | F. Hoffmann-La Roche Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;France;Mexico;Canada;Argentina;Spain;Peru;Chile;United Kingdom;Sweden | ||
| 3 | EUCTR2011-004349-42-SE (EUCTR) | 29/06/2012 | 02/05/2012 | A study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome | A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome. | Fragile X Syndrome (FXS) MedDRA version: 14.1;Level: LLT;Classification code 10025463;Term: Major depressive disorder, single episode;System Organ Class: 100000004873;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] | Product Name: mGlu5 antagonist Product Code: Ro 491-7523/F18 Other descriptive name: mGlu5 antagonist Product Name: mGlu5 antagonist Product Code: Ro 491-7523/F19 Other descriptive name: mGlu5 antagonist | F. Hoffmann-La Roche Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 180 | France;United States;Mexico;Canada;Argentina;Spain;Peru;Chile;United Kingdom;Sweden |